Clinical Trial Detail

NCT ID NCT02869633
Title Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

mantle cell lymphoma

follicular lymphoma

Hodgkin's lymphoma

chronic lymphocytic leukemia

Therapies

Ibrutinib

Age Groups: adult senior

Additional content available in CKB BOOST